



#4/B
12/10/01

Patent Docket P1134R2C2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of Avi J. Ashkenazi et al. Serial No.: 09/896,096 Filed: June 28, 2001 For: Dcr3 Polypeptide, A TNFR Homolog	Group Art Unit: To be assigned Examiner: To be assigned CERTIFICATE OF Express MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service via Express Mail, Express Mail No. EL599583847US in an envelope to: Assistant Commissioner of Patents, Washington, D.C. 20231 on August <u>13</u> , 2001 <i>Diane L. Marschang</i> Diane L. Marschang
---	--

02/16/2001 SPIRITAI 0000019 070330 02033033

01 FC:103
02 FC:102

72.00 CH
400.00 CH

PRELIMINARY AMENDMENT

Assistant Commissioner of Patents
Washington; D.C. 20231

SIR:

The present Continuation Application was filed on June 28, 2001. Entry of the following Preliminary Amendment is respectfully requested prior to examination on the merits.

In the specification:

On pages 2-3, in the paragraph on lines 31-42 and lines 1-6, the text has been amended to read:

--Induction of various cellular responses mediated by such TNF family cytokines is believed to be initiated by their binding to specific cell receptors. Two distinct TNF receptors of approximately 55-kDa (TNFR1) and 75-kDa (TNFR2) have been identified [Hohmann et al., J. Biol. Chem., 264:14927-14934 (1989); Brockhaus et al., Proc. Natl. Acad. Sci., 87:3127-3131 (1990); EP 417,563, published March 20, 1991] and human and mouse cDNAs corresponding to both receptor types have been isolated and characterized [Loetscher et al., Cell, 61:351 (1990); Schall et al., Cell, 61:361 (1990);